neodymium has been researched along with brimonidine tartrate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artunay, O; Bahcecioglu, H; Rasier, R; Sengul, A; Unal, M; Yuzbasioglu, E | 1 |
| Çakmak, K; Erbil, H; Korkmaz, Ş; Mesci, C | 1 |
2 trial(s) available for neodymium and brimonidine tartrate
| Article | Year |
|---|---|
Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Capsule Opacification; Cataract; Cloprostenol; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Posterior Capsule of the Lens; Quinoxalines; Tonometry, Ocular | 2010 |
Comparing the effects and safety of dorzolamide hydrochloride + timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lasers, Solid-State; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Sulfonamides; Thiophenes; Timolol; Yttrium | 2022 |